Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine

被引：98

作者：

Núñez, M ^{[1
]}

Pérez-Olmeda, M ^{[1
]}

Díaz, B ^{[1
]}

Ríos, P ^{[1
]}

González-Lahoz, J ^{[1
]}

Soriano, V ^{[1
]}

机构：

[1] Inst Salud Carlos III, Infect Dis Serv, Madrid, Spain

来源：

AIDS | 2002年 / 16卷 / 17期

关键词：

D O I：

10.1097/00002030-200211220-00023

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Treatment of hepatitis B virus (HBV) with lamivudine may not completely suppress viral replication and often fails as a result of lamivudine resistance. Tenofovir is a new HIV inhibitor with further activity against HBV, which was explored in 12 HBV/HIV-co-infected patients with detectable levels of serum HBV-DNA, despite receiving a lamivudine-containing antiretroviral regimen. Lamivudine-resistance mutations were found in HBV from seven patients., HBV-DNA levels dropped a median of 3.78 logs from baseline to 24 weeks. Tenofovir was very effective at reducing HBV-DNA levels in HIV/HBV-co-infected patients carrying either wild-type or lamivudine-resistant viruses.

引用

页码：2352 / 2354

页数：3

共 13 条

[1] Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study [J].